Can Immediate Post-injury Fluoxetine Improve the Recovery Trajectories of Victims in Bodily Trauma?

Sponsor
University of Florida (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06046859
Collaborator
(none)
200
1
2
37
5.4

Study Details

Study Description

Brief Summary

With this prospective double-blinded, placebo controlled clinical trial we hypothesize that immediate (post-injury) intervention with Fluoxetine will prevent/mitigate the development of negative psychiatric symptomology such as PTSD and depression for victims of bodily trauma. We also hypothesize that immediate use of Fluoxetine will decrease subjects' pain, pain interference and opioid use without changing our standard of care post-injury pain medication regimen. Enrolled subjects will be randomized to Fluoxetine or placebo at their index hospitalization.

Condition or Disease Intervention/Treatment Phase
Early Phase 1

Detailed Description

Upwards of 40-85% survivors of bodily trauma (in the civilian world most commonly motor vehicle accidents, falls and assaults), develop moderate to severe negative psychiatric symptomology following their injuries. (2,7) This symptomology can persist for years; at least 20% of patients with musculoskeletal trauma, specifically, display symptomology consistent with post-traumatic stress disorder (PTSD) symptomology up to three years following their injury. (8) Poor mental health outcomes are an independent risk factor for poor physical and social outcomes. (9,10) These symptoms, which are highly impairing, are complicated and heightened by loss of work/income following trauma, limited financial and social resources, and a large percentage of the population being uninsured/underinsured. Research has demonstrated that the pressures of poverty and low socioeconomic status alone predispose to PTSD symptomology and poor coping mechanisms, and this is compounded by decreased ability to obtain and pay for mental health care by those impoverished. There are significant barriers to mental health care for many adults, and these hurdles are even more insurmountable for those under or uninsured, minorities, and those in rural communities. (11) Very few victims of trauma who screen positive for psychological disorder receive mental health services following injury (12% at 3-months from injury), and if so, it is far removed from the injury (22% at 24-months from injury).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Masking Description:
Researchers collecting survey data will be blinded to patients' intervention status.
Primary Purpose:
Treatment
Official Title:
Can Immediate Post-injury Fluoxetine Improve the Recovery Trajectories of Victims in Bodily Trauma?
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Nov 30, 2026
Anticipated Study Completion Date :
Nov 30, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Subjects randomized to get Fluoxetine therapy

Subjects will be randomized to take Fluoxetine (10mg by mouth per day for first 14 days then 20 mg by mouth for 9 months). The randomized drug will be prescribed by the study team on the day of randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy at the 2 week, 3 month, and 6 month follow-up visits

Drug: Fluoxetine
Subjects will be randomized to take Fluoxetine (10mg by mouth per day for first 14 days then 20 mg by mouth for 9 months). The randomized drug will be prescribed by the study team on the day of randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy at the 2 week, 3 month, and 6 month follow-up visits

Active Comparator: Subjects randomized to Placebo

When a patient is enrolled, the inpatient research pharmacy will dispense the appropriately randomized medication in a visually similar, over-encapsulated form as Fluoxetine

Drug: Placebo
When a patient is enrolled, the inpatient research pharmacy will dispense the appropriately randomized medication in a visually similar, over-encapsulated form as Fluoxetine

Outcome Measures

Primary Outcome Measures

  1. Beck Dression Inventory survey, in the post injury period for patients with musculoskeletal trauma. [Baseline up to 12 months]

    BDI-II Beck Depression Inventory: higher score means worse outcome; 0-63.

Secondary Outcome Measures

  1. Patient reported pain scores, PROMIS Pain Interference, will be recorded at each visit. [Baseline up to 12 months]

    PROMIS PI: Pain Interference; A score of 50 is average; Adaptive so no minimum/maximum values.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Admitted to UF Health for trauma resulting in:

  • One or more extremity fractures requiring surgery

  • Pelvic Fracture

  • Chest/abdominal Injury requiring intervention in operating room

  • Polytrauma (multiple organ systems/multiple fractures) or Beck Depression Inventory (BDI-II) ≥ 14

Exclusion Criteria:
  • Severe Traumatic Brain Injury or cognitively not able to participate in surveys. (Glasgow Coma Scale 3-8)

  • Other psychiatric conditions on current medical management (SSRI)

  • Incarceration or Pregnancy

  • Expected Injury Survival of less than 90 days

  • Medical or physical condition in opinion of investigators that would preclude safe study participation

  • Unable to provide informed consent due to language or other barriers

  • Current or previous substance abuse (excluding cannabinoids and alcohol)

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Florida Gainesville Florida United States 32608

Sponsors and Collaborators

  • University of Florida

Investigators

  • Principal Investigator: Jennifer Hagan, MD, University of Florida

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Florida
ClinicalTrials.gov Identifier:
NCT06046859
Other Study ID Numbers:
  • IRB202301506
First Posted:
Sep 21, 2023
Last Update Posted:
Sep 21, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 21, 2023